Development and Validation of the Cluster Headache Screening Questionnaire.
cluster headache
diagnosis
migraine
prevalence
questionnaire
screening
Journal
Journal of clinical neurology (Seoul, Korea)
ISSN: 1738-6586
Titre abrégé: J Clin Neurol
Pays: Korea (South)
ID NLM: 101252374
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
08
2018
revised:
17
09
2018
accepted:
19
09
2018
entrez:
9
1
2019
pubmed:
9
1
2019
medline:
9
1
2019
Statut:
ppublish
Résumé
Cluster headache (CH) is frequently either not diagnosed or the diagnosis is delayed. We addressed this issue by developing the self-administered Cluster Headache Screening Questionnaire (CHSQ). Experts selected items from the diagnostic criteria of CH and the characteristics of migraine. The questionnaire was administered to first-visit headache patients at nine headache clinics. The finally developed CHSQ included items based on the differences in responses between CH and non-CH patients, and the accuracy and reliability of the scoring model were assessed. Forty-two patients with CH, 207 migraineurs, 73 with tension-type headache, and 18 with primary stabbing headache were enrolled. The CHSQ item were scored as follows: 3 points for ipsilateral eye symptoms, agitation, and duration; 2 points for clustering patterns; and 1 point for the male sex, unilateral pain, disability, ipsilateral nasal symptoms, and frequency. The total score of the CHSQ ranged from 0 to 16. The mean score was higher in patients with CH than in non-CH patients (12.9 vs. 3.4, The CHSQ is a reliable screening tool for the rapid identification of CH.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Cluster headache (CH) is frequently either not diagnosed or the diagnosis is delayed. We addressed this issue by developing the self-administered Cluster Headache Screening Questionnaire (CHSQ).
METHODS
METHODS
Experts selected items from the diagnostic criteria of CH and the characteristics of migraine. The questionnaire was administered to first-visit headache patients at nine headache clinics. The finally developed CHSQ included items based on the differences in responses between CH and non-CH patients, and the accuracy and reliability of the scoring model were assessed.
RESULTS
RESULTS
Forty-two patients with CH, 207 migraineurs, 73 with tension-type headache, and 18 with primary stabbing headache were enrolled. The CHSQ item were scored as follows: 3 points for ipsilateral eye symptoms, agitation, and duration; 2 points for clustering patterns; and 1 point for the male sex, unilateral pain, disability, ipsilateral nasal symptoms, and frequency. The total score of the CHSQ ranged from 0 to 16. The mean score was higher in patients with CH than in non-CH patients (12.9 vs. 3.4,
CONCLUSIONS
CONCLUSIONS
The CHSQ is a reliable screening tool for the rapid identification of CH.
Identifiants
pubmed: 30618222
pii: 15.90
doi: 10.3988/jcn.2019.15.1.90
pmc: PMC6325359
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90-96Subventions
Organisme : Korean Neurological Association
ID : KNA-16-MI-09
Informations de copyright
Copyright © 2019 Korean Neurological Association.
Déclaration de conflit d'intérêts
Dr. Cho was involved as a site investigator of multicenter trial sponsored by Otsuka Korea, Eli Lilly and Company, Korea BMS, and Eisai Korea, and worked as an advisory member for Teva, and received research support from Hallym University Research Fund 2016 and received Academic award of Myung In Pharm.Ltd, and received lecture honoraria from Yuyu Pharmaceutical Company. All other authors have no financial conflicts of interest.
Références
Headache. 2000 Oct;40(9):730-5
pubmed: 11091291
Cephalalgia. 2002 Mar;22(2):94-100
pubmed: 11972575
Behav Genet. 2002 Mar;32(2):153-61
pubmed: 12036113
Cephalalgia. 2002 May;22(4):256-9
pubmed: 12100086
J Gen Intern Med. 2002 Aug;17(8):646-9
pubmed: 12213147
Lancet Neurol. 2002 Aug;1(4):251-7
pubmed: 12849458
J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1123-5
pubmed: 12876249
Neurology. 2003 Aug 12;61(3):375-82
pubmed: 12913201
Cephalalgia. 2004 Aug;24(8):631-8
pubmed: 15265051
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Neurology. 2005 Feb 8;64(3):469-74
pubmed: 15699377
Headache. 2005 Jun;45(6):644-52
pubmed: 15953296
Cephalalgia. 2007 Jun;27(6):504-9
pubmed: 17428298
Cephalalgia. 2007 Jun;27(6):535-41
pubmed: 17459083
Cephalalgia. 2007 Sep;27(9):1014-9
pubmed: 17666085
Cephalalgia. 2008 Jun;28(6):614-8
pubmed: 18422717
J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1116-9
pubmed: 18931007
Headache. 2009 Jan;49(1):64-70
pubmed: 19133334
Cephalalgia. 2009 Sep;29(9):949-52
pubmed: 19250289
Lancet Neurol. 2011 Oct;10(10):891-7
pubmed: 21903477
Cephalalgia. 2011 Dec;31(16):1664-72
pubmed: 21994114
J Clin Neurol. 2012 Sep;8(3):204-11
pubmed: 23091530
J Headache Pain. 2013 Feb 18;14:14
pubmed: 23565739
Cephalalgia. 2013 Aug;33(11):924-31
pubmed: 23624341
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
J Headache Pain. 2014 Sep 01;15:56
pubmed: 25178541
Cephalalgia. 2016 May;36(6):547-51
pubmed: 26395893
J Korean Med Sci. 2016 Jan;31(1):106-13
pubmed: 26770045
Cephalalgia. 2016 Dec;36(14):1334-1340
pubmed: 26858260
Headache. 2016 Jul;56(7):1093-106
pubmed: 27432623
J Headache Pain. 2016 Dec;17(1):79
pubmed: 27596922
Headache. 2017 Feb;57(2):290-297
pubmed: 27861832
J Korean Med Sci. 2017 Mar;32(3):502-506
pubmed: 28145655